XML 21 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Segment Reporting
 3 Months Ended
Mar. 31, 2012
Segment Reporting [Abstract]  
SEGMENT REPORTING
(11) SEGMENT REPORTING

At March 31, 2012, the Company has determined that its subsidiaries, ZMI, ZND and ZMS each represent reporting segments. This determination was made based on the nature of the products and services offered to customers or the nature of the function in the organization. The accounting policies for each of these segments are the same as those described in Note 2, and inter-segment transactions are eliminated. Net revenue was primarily generated from sales in the United States. The tables below summarize information about reported segments for the three months ended March 31, 2012 and 2011.

Zynex Medical (ZMI):

ZMI designs, manufactures and markets U.S. Food and Drug Administration (“FDA”) cleared medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMI devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (“IF”), neuromuscular electrical stimulation (“NMES”) and transcutaneous electrical nerve stimulation (“TENS”). ZMI products require a physician’s prescription, authorization or order before they can be dispensed in the U.S. ZMI considers the physician’s prescription as an “order”, and it is on this basis that product is provided to the patient and ZMI either bills the patient directly, bills the patient’s private insurance or bills Medicare or Medicaid for payment.

Zynex NeuroDiagnostics (ZND):

ZND was formed to market, through product development and acquisitions, EMG, EEG, sleep pattern, auditory and nerve conductivity neurological diagnosis devices to hospitals and clinics worldwide, through the utilization of existing ZMI diagnostic EMG technology. As described in Note 3, on March 9, 2012, ZND acquired NeuroDyne. NeuroDyne is a manufacturer of advanced medical devices for non-invasive measurement of sEMG and autonomic nervous systems.

 

Zynex Monitoring Solutions (ZMS):

ZMS was formed to develop and market medical devices for non-invasive cardiac monitoring. ZMS activities to date represent research and product development, specifically related to a non-invasive blood volume monitor. The blood volume monitor is a non-invasive medical device for monitoring central blood volume that would be used in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery.

 

                                 
    ZMI     ZND     ZMS     TOTAL  

THREE MONTHS ENDED MARCH 31, 2012

                                

Sales

     8,869       75       —         8,944  

Gross profit

     7,081       50       —         7,131  

Total assets

     23,098       781       9       23,888  
         

THREE MONTHS ENDED MARCH 31, 2011

                                

Sales

     6,633       —         —         6,633  

Gross profit

     5,189       —         —         5,189  

Total assets

     16,701       23       18       16,742